SCHEMBL25756893

SCHEMBL25756893

CCn1cnc2c(c(I)cn2CC2CC2)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.39
CYP11B2 P19099 3/20 0.38
SIGMAR1 Q99720 1/20 0.37
HSD17B13 Q7Z5P4 1/20 0.36
RAB9A P51151 1/20 0.34
PDE4A P27815 2/20 0.34
ADORA2A P29274 2/20 0.34
PDE4B Q07343 2/20 0.34
PDE4C Q08493 2/20 0.34
PDE4D Q08499 2/20 0.34
ADORA2B P29275 1/20 0.34
TSHR P16473 1/20 0.34
GRM1 Q13255 2/20 0.33
YTHDC1 Q96MU7 1/20 0.32
PKM P14618 1/20 0.32
BRAF P15056 1/20 0.32
KMT2A Q03164 1/20 0.32
MAPK13 O15264 1/20 0.31
MAPK12 P53778 1/20 0.31
MAPK11 Q15759 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25756836 0.80 RAB9A (0.38) RAB9APDE4AADORA2APDE4BPDE4C
SCHEMBL21262557 0.80 SMN1; SMN2 (0.45) ACACBSIGMAR1HSD17B13TSHRKMT2A
SCHEMBL27199385 0.78 RAB9A (0.36) RAB9APDE4AADORA2APDE4BPDE4C
SCHEMBL27199465 0.76 PDE4A (0.35) RAB9APDE4AADORA2APDE4BPDE4C
SCHEMBL25756890 0.73 ACACB (0.38) ACACBCYP11B2SIGMAR1
SCHEMBL398112 0.70 DYRK3 (0.54) ACACBRAB9A
SCHEMBL400113 0.70 ADK (0.44) ACACBYTHDC1KMT2A
SCHEMBL25757934 0.68 ALDH1A1 (0.32) PDE4AADORA2APDE4BPDE4CPDE4D
SCHEMBL15265817 0.65 ADORA2B (0.33) PDE4AADORA2APDE4BPDE4CPDE4D
SCHEMBL17749198 0.65 ADK (0.42) ACACBYTHDC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
EP-4448514-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF Lynk Pharmaceuticals Co. Ltd. (CN) 2024-10-23 EP disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 ACACB 1956/4885CYP11B2 3287/4885SIGMAR1 4632/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 ACACB 1956/4885CYP11B2 3287/4885SIGMAR1 4632/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 ACACB 1956/4885CYP11B2 3287/4885SIGMAR1 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.